knowledge -WSS

knowledge

author：knowledge 2025-09-29 16:25:30 - browse：437

In 2018, New York University became the first U.S. medical school to go tuition free. Since then, a handful of others have followed with many more considering similar programs. One hope for free tuition endeavors is that lower post-graduation debt will increase the number of med students who choose lower-paying, desperately needed careers in primary care and pediatrics. But free tuition programs are not necessarily delivering on that promise.

In this episode of the First Opinion Podcast, University of Pennsylvania oncologist and researcher Ezekiel Emanuel and Matthew Guido, a project manager in the Healthcare Transformation Institute, discuss their original research on tuition-free programs with former host Pat Skerrett, who is filling in while Torie Bosch is on maternity leave. They make the case that medical school debt is only one of many factors that influence new doctors to choose less-popular specialties and geographic locations for their residencies. Other factors including prestige, the lifetime earning potential of higher-pay specialties, which can add several millions dollars over a career, can have more sway than student debt alone. This is especially important, they say, as needs for patients with chronic illnesses are rapidly outpacing the number of primary care physicians available to give that care.

“We have undervalued both philosophically and also financially the complications of managing chronic illness,” Emanuel says. “Can we rebalance the payment system that rewards the improvements in health and therefore the attention to chronic illness through primary care?”

You can read more about Emanuel and Guido’s opinions in their essay “Free med school tuition won’t solve the shortage of primary care physicians.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Stigma and the return of syphilis

focus

WSS

A disappointing year of Humira biosimilars

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

The Readout: Gilead, Bernie Sanders, and other pharma news

Antibiotic resistance nearly killed me, so I'm raising awareness of it

'Revelatory' study finds a smoking impact that remains after quitting

David Sabatini, ex

focus

knowledge

focus

Affirmative action in medical school literally saved lives

Average age of first period drops to 11.9 years, study shows

Medical records are filled with copy

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

As demand for Covid shots wanes, Moderna seeks its next success

Doctors' information doesn't help them choose wisely when sick

Psychedelics group wrestles with new pharma identity

Health insurers say they are turning to AI to cut costs, improve care

BioMarin wins approval for gene therapy to treat hemophilia A

Adam's Biotech Scorecard: Do Sarepta's exon

explore

KalVista pill reduced swelling 'attacks' caused by genetic disease

Stigma and the return of syphilis

Readout LOUD podcast: How biotech is using artificial intelligence

Readout LOUD podcast: How biotech is using artificial intelligence

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

What will save rural psychiatry services? Higher Medicaid payments

entertainment

focus

focus

hotspot